Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TSC-204-A0201 |
Synonyms | |
Therapy Description |
TSC-204-A0201 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting the MAGE-A1 antigen presented on HLA-A*02:01, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of MAGE-A1-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TSC-204-A0201 | TSC 204-A0201|TSC204-A0201 | TSC-204-A0201 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting the MAGE-A1 antigen presented on HLA-A*02:01, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of MAGE-A1-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05973487 | Phase I | TSC-200-A0201 + TSC-204-C0702 TSC-203-A0201 TSC-201-B0702 + TSC-204-A0201 TSC-200-A0201 TSC-204-A0101 + TSC-204-A0201 TSC-201-B0702 TSC-201-B0702 + TSC-204-C0702 TSC-204-A0101 TSC-204-A0101 + TSC-204-C0702 TSC-204-A0201 + TSC-204-C0702 TSC-200-A0201 + TSC-204-A0201 TSC-204-C0702 TSC-203-A0201 + TSC-204-C0702 TSC-204-A0201 TSC-203-A0201 + TSC-204-A0201 TSC-201-B0702 + TSC-204-A0101 TSC-201-B0702 + TSC-203-A0201 TSC-200-A0201 + TSC-204-A0101 TSC-200-A0201 + TSC-203-A0201 TSC-203-A0201 + TSC-204-A0101 TSC-200-A0201 + TSC-201-B0702 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | Recruiting | USA | 0 |